Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Azria, David ^a,b   Bibeau, Frederic ^a   Barbier, Nicolas ^a   Zouhair, Abderrahim ^a,c   Lemanski, Claire ^a   Rouanet, Philippe ^a   Ychou, Marc ^a,b   Senesse, Pierre ^a   Ozsahin, Mahmut ^c   Pèlegrin, André ^b   Dubois, Jean Bernard ^a   Thèzenas, Simon ^a  

^a CENTRE VAL D AURELLE   (France)

^b INSERM   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TUMOR MARKER;

ADULT; AGED; ANUS SPHINCTER; ARTICLE; CANCER CENTER; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; CLINICAL OBSERVATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHOTON; PREDICTION; PREOPERATIVE PERIOD; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIATION DOSE; RECTUM CANCER; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR BIOPSY; TUMOR CELL; BIOPSY; BIOSYNTHESIS; DISEASE COURSE; DISEASE FREE SURVIVAL; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIATION RESPONSE; RADIOTHERAPY; RECTUM TUMOR; RECURRENT DISEASE; REGRESSION ANALYSIS; RISK; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; RECURRENCE; REGRESSION ANALYSIS; RISK; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 26844465462     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-62     Document Type: Article

References (53)

1. Kane JM, Petrelli NJ: Controversies in the surgical management of rectal cancer. Semin Radiat Oncol 2003, 13:403-418.
2. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
3. Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001, 358:1291-1304.
4. Wiggenraad R, Tamminga R, Blok P, Rouse R, Hermans J: The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1998, 41:29-35.
5. Lopez-Crapez E, Ychou M, Thèzenas S, Simony-Lafontaine J, Thirion A, Azria D, Bibeau F, Grenier J, Senesse P: Multilevel analysis of p53 status and response to preoperative radiotherapy in rectal cancer: results of a prospective evaluation. B J Cancer, in press.
6. Tannapfel A, Nusslein S, Fietkau R, Katalinic A, Kockerling F, Wittekind C: Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 1998, 41:585-591.
7. International Commission on Radiation Units and Measurements (ICRU): Prescribing, recording, and reporting photon beam therapy. 24 Bethesda, Maryland; 2001.
8. Sobin L, Wittekind C (UICC). eds. TNM Classification of Malignant Tumours. New York: Wiley-Liss; 1997.
9. Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997, 410:83-86.
10. Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 1987, 84:7159-7163.
11. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992, 23:974-979.
12. Schmidt-Ullrich RK, Dent P, Grant S, Mikkelsen RB, Valerie K: Signal transduction and cellular radiation responses. Radiat Res 2000, 153:245-257.
13. Wollman R, Yahalom J, Maxy R, Pinto J, Fuks Z: Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys 1994, 30:91-98.
14. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS, Muschel RJ: Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002, 8:885-892.
15. Barker FG, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, Wara WM, Berger MS, Chen P, Israel MA, Aldape KD: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001, 51:410-418.
16. Balaban N, Moni J, Shannon M, Dang L, Murphy E, Goldkorn T: The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1996, 1314:147-156.
17. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK, Chen PB: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997, 15:1191-1197.
18. Carter S, Auer KL, Reardon DB, Birrer M, Fisher PB, Valerie K, Schmidt-Ullrich R, Mikkelsen R, Dent P: Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene 1998, 16:2787-2796.
19. Kavanagh BD, Dent P, Schmidt-Ullrich RK, Chen P, Mikkelsen RB: Calcium-dependent stimulation of mitogen-activated protein kinase activity in A431 cells by low doses of ionizing radiation. Radiat Res 1998, 149:579-587.
20. Goldkorn T, Balaban N, Shannon M, Matsukuma K: EGF receptor phosphorylation is affected by ionizing radiation. Biochim Biophys Acta 1997, 1358:289-299.
21. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999, 10:2493-2506.
22. David M, Wong L, Flavell R, Thompson SA, Wells A, Larner AC, Johnson GR: STAT activation by epidermal growth factor (EGF) and amphiregulin. Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1. J Biol Chem 1996, 271:9185-9188.
23. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000, 97:4227-4232.
24. Park OK, Schaefer TS, Nathans D: In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci U S A 1996, 93:13704-13708.
25. Akimoto T, Hunter NR, Buchmiller L, Mason K, Kian Ang K, Milas L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999, 5:2884-2890.
26. Sheridan MT, O'Dwyer T, Seymour CB, Mothersill CE: Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 1997, 5:180-186.
27. Christensen ME, Therkildsen MH, Poulsen SS, Bretlau P: Immunoreactive transforming growth factor alpha and epidermal growth factor in oral squamous cell carcinomas. J Pathol 1993, 169:323-328.
28. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F, Milano G: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993, 11:1873-1878.
29. Grandis JR, Tweardy DJ: TGF-alpha and EGFR in head and neck cancer. J Cell Biochem 1993, Suppl 27F:188-191.
30. Lee CS, Redshaw A, Boag G: Epidermal growth factor receptor immunoreactivity in human laryngeal squamous cell carcinoma. Pathology 1997, 29:251-254.
31. Maiorano E, Favia G, Maisonneuve P, Viale G: Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa. J Pathol 1998, 185:167-174.
32. Santini J, Formento JL, Francoual M, Milano G, Schneider M, Dassonville O, Demard F: Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991, 13:132-139.
33. Etienne MC, Pivot X, Formento JL, Bensadoun RJ, Formento P, Dassonville O, Francoual M, Poissonnet G, Fontana X, Schneider M, Demard F, Milano G: A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 1999, 79:1864-1869.
34. Miyaguchi M, Olofsson J, Hellquist HB: Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy. Clin Otolaryngol 1991, 16:466-469.
35. Wen QH, Miwa T, Yoshizaki T, Nagayama I, Furukawa M, Nishijima H: Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope 1996, 106:884-888.
36. Almadori G, Cadoni G, Galli J, Ferrandina G, Scambia G, Exarchakos G, Paludetti G, Ottaviani F: Epidermal growth factor receptor expression in primary laryngeal cancer: an independent prognostic factor of neck node relapse. Int J Cancer 1999, 84:188-191.
37. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002, 62:7350-7356.
38. Magne N, Pivot X, Bensadoun RJ, Guardiola E, Poissonnet G, Dassonville O, Francoual M, Formento JL, Demard F, Schneider M, Milano G: The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo- radiotherapy. Eur J Cancer 2001, 37:2169-2177.
39. Chua DT, Nicholls JM, Sham JS, Au GK: Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59:11-20.
40. Steele RJ, Kelly P, Ellul B, Eremin O: Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990, 77:1352-1354.
41. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993, 71:2454-2460.
42. Giralt J, Eraso A, Armengol M, Rossello J, Majo J, Ares C, Espin E, Benavente S, de Torres I: Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2002, 54:1460-1465.
43. Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997, 12:19-23.
44. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, van Custem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
45. Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ, Pemberton JH, Wolff BG: Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992, 174:27-32.
46. Obrand DI, Gordon PH: Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997, 40:15-24.
47. Konn M, Morita T, Hada R, Yamanaka Y, Sasaki M, Munakata H, Suzuki H, Inoue S, Endoh M, Sugiyama Y: Survival and recurrence after low anterior resection and abdominoperineal resection for rectal cancer: the results of a long-term study with a review of the literature. Surg Today 1993, 23:21-30.
48. Michelassi F, Vannucci L, Ayala JJ, Chappel R, Goldberg R, Block GE: Local recurrence after curative resection of colorectal adenocarcinoma. Surgery 1990, 108:787-792.
49. Arbman G, Nilsson E, Hallbook O, Sjodahl R: Local recurrence following total mesorectal excision for rectal cancer. Br J Surg 1996, 83:375-379.
50. de Haas-Kock DF, Baeten CG, Jager JJ, Langendijk JA, Schouten LJ, Volovics A, Arends JW: Prognostic significance of radial margins of clearance in rectal cancer. Br J Surg 1996, 83:781-785.
51. Bjerkeset T, Edna TH: Rectal cancer: the influence of type of operation on local recurrence and survival. Eur J Surg 1996, 162:643-648.
52. Azria D, Larbouret C, Robert B, Culine S, Ychou M, Verrelle P, Dubois JB, Pelegrin A: Anti-EGF receptors and radiation therapy: current translational research and early clinical trials. Bull Cancer 2003, 90:202-212.
53. Sartor CI: Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol 2003, 13:22-30.